Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW001 Inhalation Solution in Infants With RSV Infection
CTR20230275Phase 2Completed
- Sponsor
- Sciwind Biosciences
- Start
- Jan 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of xw001 in respiratory syncytial virus disease (RSV), sponsored by Sciwind Biosciences. Started Jan 2023; status: completed.
02
Drugs
xw001
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20230275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230275.